Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C181794> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- NCIT_C181794 IAO_0000115 "A chemoimmunotherapy regimen consisting of nab-paclitaxel and pembrolizumab that can be used for the treatment of recurrent and metastatic hormone receptor-negative, HER-2 (EGFR2; ErbB2)-negative and PD-L1-positive breast cancer." @default.
- NCIT_C181794 NCIT_NHC0 "C181794" @default.
- NCIT_C181794 NCIT_P106 "Therapeutic or Preventive Procedure" @default.
- NCIT_C181794 NCIT_P108 "Nab-Paclitaxel/Pembrolizumab Regimen" @default.
- NCIT_C181794 NCIT_P208 "CL1664631" @default.
- NCIT_C181794 NCIT_R123 NCIT_C106432 @default.
- NCIT_C181794 NCIT_R123 NCIT_C124946 @default.
- NCIT_C181794 NCIT_R123 NCIT_C128037 @default.
- NCIT_C181794 NCIT_R123 NCIT_C141144 @default.
- NCIT_C181794 NCIT_R123 NCIT_C143250 @default.
- NCIT_C181794 NCIT_R123 NCIT_C163758 @default.
- NCIT_C181794 NCIT_R123 NCIT_C186664 @default.
- NCIT_C181794 NCIT_R123 NCIT_C1908 @default.
- NCIT_C181794 NCIT_R123 NCIT_C1909 @default.
- NCIT_C181794 NCIT_R123 NCIT_C20401 @default.
- NCIT_C181794 NCIT_R123 NCIT_C25974 @default.
- NCIT_C181794 NCIT_R123 NCIT_C2688 @default.
- NCIT_C181794 NCIT_R123 NCIT_C273 @default.
- NCIT_C181794 NCIT_R123 NCIT_C274 @default.
- NCIT_C181794 NCIT_R123 NCIT_C307 @default.
- NCIT_C181794 NCIT_R123 NCIT_C308 @default.
- NCIT_C181794 NCIT_R123 NCIT_C61078 @default.
- NCIT_C181794 NCIT_R123 NCIT_C67437 @default.
- NCIT_C181794 normalizedInformationContent "100" @default.
- NCIT_C181794 referenceCount "1" @default.
- NCIT_C181794 hasExactSynonym "Abraxane/Keytruda" @default.
- NCIT_C181794 hasExactSynonym "Albumin-bound Paclitaxel/Pembrolizumab Regimen" @default.
- NCIT_C181794 hasExactSynonym "Nab-Paclitaxel-Pembrolizumab Regimen" @default.
- NCIT_C181794 hasExactSynonym "Nab-Paclitaxel-Pembrolizumab" @default.
- NCIT_C181794 hasExactSynonym "Nab-Paclitaxel/Pembrolizumab Regimen" @default.
- NCIT_C181794 hasExactSynonym "Nab-Paclitaxel/Pembrolizumab" @default.
- NCIT_C181794 hasExactSynonym "Pembrolizumab Plus Nab-Paclitaxel" @default.
- NCIT_C181794 hasExactSynonym "Pembrolizumab-Nab-Paclitaxel" @default.
- NCIT_C181794 hasExactSynonym "Pembrolizumab/Nab-Paclitaxel Regimen" @default.
- NCIT_C181794 hasExactSynonym "Pembrolizumab/Nab-Paclitaxel" @default.
- NCIT_C181794 inSubset NCIT_C160950 @default.
- NCIT_C181794 inSubset NCIT_C160952 @default.
- NCIT_C181794 type Class @default.
- NCIT_C181794 isDefinedBy ncit.owl @default.
- NCIT_C181794 label "Nab-Paclitaxel/Pembrolizumab Regimen" @default.
- NCIT_C181794 subClassOf B0d9bbbaea4f6ef7fc31719c5cce784e5 @default.
- NCIT_C181794 subClassOf B4902e1f625e3aff0d3d2f53f944bb8bf @default.
- NCIT_C181794 subClassOf B7596838b7c68de30bd88318ada319fec @default.
- NCIT_C181794 subClassOf Bdd3098b956fe7fdb360a631249c52efb @default.
- NCIT_C181794 subClassOf NCIT_C12218 @default.
- NCIT_C181794 subClassOf NCIT_C181794 @default.
- NCIT_C181794 subClassOf NCIT_C62634 @default.
- NCIT_C181794 subClassOf NCIT_C63358 @default.